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ABSTRACT 
 
Objective: Hepatocellular carcinoma (HCC) is the most prevalent primary tumor of 
the liver. About a third of these tumors presents activating mutations of the β-catenin 
gene. The molecular pathogenesis of HCC has been elucidated, but mortality 
remains high and new therapeutic approaches, including treatments based on 
microRNAs, are required. We aimed to identify candidate microRNAs, regulated by 
β-catenin, potentially involved in liver tumorigenesis. Design: We used a mouse 
model, in which β-catenin signaling was overactivated exclusively in the liver, by the 
tamoxifen-inducible and Cre-Lox-mediated inactivation of the Apc gene. This model 
develops tumors with properties similar to human HCC. Results: We found that miR-
34a was regulated by β-catenin, and significantly induced by the overactivation of β-
catenin signaling in mouse tumors and in HCC patients. An inhibitor of miR-34a 
(LNA-34a) exerted anti-proliferative activity in primary cultures of hepatocyte. This 
inhibition of proliferation was associated with a decrease in cyclin D1 levels, 
orchestrated principally by HNF-4α, a target of miR-34a considered to act as a tumor 
suppressor in the liver. In vivo, LNA-34a approximately halved progression rates for 
tumors displaying β-catenin activation together with an activation of caspases 2 and 
3.Conclusion: This work demonstratesthe key oncogenic role of miR-34a in liver 
tumors with β-catenin gene mutations. We suggest that patients diagnosed with HCC 
with β-catenin mutations could be treated with an inhibitor of miR-34a. The potential 
value of this strategy lies in the modulation of the tumor suppressor HNF-4α, which 
targets cyclin D1, and the induction of a pro-apoptotic program. 
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SUMMARY BOX  
 
What is already known on this subject ? 
 
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer 
and the third leading cause of death by cancer worldwide, due to the lack of effective 
treatments. We, and others, have shown that mutations of the CTNNB1 gene, 
encoding β-catenin, are observed in 15 to 40% of HCCs. HCCs with β-catenin 
mutation constitute one of the two subclasses of HCC, and are thought to follow a 
particular pattern of pathogenesis.  
 
What are the new findings? 
 
Using a transgenic mouse model developing tumors with β-catenin activation, we 
provide the first evidence of an oncogenic role of miR-34a in liver tumors with β-
catenin mutations. An inhibitor against miR-34a slows tumor progression, and inhibits 
the development of new tumors in this model.  
 
How might it impact on clinical practice in the foreseeable future? 
 
These findings call into question the preclinical trial designed by 
miRNAtherapeutics, using miR-34a mimics to combat liver tumor growth. Instead, we 
provide here proof-of-concept that a locked nucleic acid-based inhibitor of miR-34a 
may be useful for treatment, exclusively in HCCs with β-catenin mutation. 
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INTRODUCTION 
 
Liver cancer is the third leading cause of cancer-related death worldwide. 
Hepatocellular carcinoma (HCC) is the most frequent form of primary liver cancer, 
which mostly affects men with cirrhosis. HCC frequently appears in a context of 
chronic liver disease caused by infection with the hepatitis B and C viruses (HBV and 
HCV, respectively), alcohol consumption, obesity or genotoxic exposure ([1] for a 
review). We, and others, have shown that mutations of the CTNNB1 gene, encoding 
β-catenin, are observed in 15 to 40% of HCCs [2, 3]. HCCs with β-catenin mutation 
constitute one of the two subclasses of HCC [4, 5], and are thought to follow a 
particular pattern of pathogenesis, as most are well differentiated, cholestatic and 
with a better prognosis [6]. Several years ago, we engineered a mouse model in 
which β-catenin signaling was overactivated exclusively in the liver, by the tamoxifen-
inducible and Cre-Lox-mediated inactivation of the Apc (ApcKO) gene, encoding a 
tumor suppressor, which is an inhibitor of the Wnt/β-catenin pathway, andthe liver 
“zonation-keeper”[7, 8]. In this model, the absence of Apc in single hepatocytes 
results in the development of β-catenin-activated liver tumors with properties similar 
to those observed in human patients [8]. IfApcis deleted in all hepatocytes, the β-
catenin signaling in hepatocytes leads to the induction of a transcriptional program 
very similar to that of human HCC with β-catenin mutation[8, 9].  
The molecular pathogenesis of HCC has been elucidated [10], but the incidence 
and mortality of HCC remain high, despite the use of the tyrosine kinase inhibitor 
sorafenib. Different therapeutic strategies could therefore be used to target tumors in 
accordance with theirpathogenic pathways. MicroRNAs (miRNAs) have recently 
emerged as potent diagnostic and prognostic biomarkers, and numbers of 
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reportsdevoted to miRNAs have shown that these molecules act as oncogenes or 
tumor suppressors[11]. The global analysis of the miRNAs expressed in liver tumors 
highlighted a miRNA signature common to all types of HCC [12-14]. A loss of miR-
122 [13], miR-29 [15], and miR-124 [16] has been described. Inversely, some 
oncogenic miRNAs have been identified: miR-21 [17], miR-221/miR-222 [18], and 
miR-224 [19]. Despite the number of global analyses, the role of miR-34a in liver 
tumorigenesis remains unclear. Even if this miRNA is currently described as a tumor 
suppressor in various cancers [20], two studies suggested that miR-34a levels 
decrease in HCCs, mainly HBV+[21, 22], while other studies reported an induction of 
miR-34a, particularly in HCC with β-cateninmutations [17, 18].  
We aimed to identify candidate microRNAs, regulated by β-catenin, potentially 
involved in liver tumorigenesis. We observed that miR-34a was overexpressed in 
response to β-catenin overactivation; the levels of miR-34a being inversely correlated 
with those of HNF-4α (hepatocyte nuclear receptor α), another key factor for 
hepatocyte differentiation, which we have shown to antagonize β-catenin function[9]. 
MiR-34a induction was observed specifically in mouse and human liver tumors with 
β-catenin mutations, and miR-34a was found to play an oncogenic role in the liver. 
These findings call into question the systematic use of miR-34a mimics to combat 
liver tumor growth (http://www.mirnarx.com/pipeline/mirna-MRX34.html). Instead, we 
provide here proof-of-concept that a locked nucleic acid (LNA)-based inhibitor of 
miR-34a may be useful for treatment, exclusively in HCCs with β-catenin mutation. 
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METHODS 
 
Animals and reagents 
Transgenic mice, liver sampling and immunostaining have been described 
elsewhere[7, 9, 23], and detailed in the supporting materials. 
 
Hepatocyte isolation 
To directly lyse hepatocytes after collagenase perfusion, i.e. for RNA or protein 
extraction, the transgenic livers were perfused six days after tamoxifen injection (1.5 
mg)as previously described[9, 23]. Non-parenchymal cells were excluded in the 
supernatant, and hepatocytes preparations were used for subsequent experiments. 
Periportal and pericentral subpopulations of wt hepatocytes were isolated by 
perfusion with digitonin and collagenase, as previously reported[24]. 
 
Cell culture  
For primary culture of hepatocytes, livers were perfused three days after tamoxifen 
injection to Apclox/lox mice, the cells were dispersed in William’s medium 
(supplemented with 10% fetal bovine serum, penicillin-streptomycin, fungizone, 25nM 
dexamethasone, insulin 4 μg/mL and 1% BSA), and plated in wells coated with rat-
tail collagen I (GIBCO).  
 
Transfection assays 
The cells were transfected 4h after plating, as described in the supporting 
materials. 
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xCELLigence assay 
Hepatocyte adhesion and cell cycle progression were measured with the 
xCELLigence system (Roche). Cells were transfected with 100 nMLNA or mimic 4 h 
after plating, as described above (see supporting Materials). The impedance was 
then measured for 48 h. 
 
Western-Blotting 
The membrane with 50μg proteins was probed overnight with a primary antibody 
against the protein of interest (see Supporting Materials), and then incubated with a 
HRP-conjugated secondary antibody (Cell Signaling) for detection with the ECL 
system (Biorad). 
 
In situ hybridization 
Sections were deparaffinized and treated with 0.1 mg/ml proteinase K, then 
hybridized for one hour at 55°C with 100 nmol digoxigenin-labeled-LNA-scramble or 
LNA-34a (Exiqon). Signals were detected with anti-digoxigenin (Roche) and 
NBT/BCIP (Roche). 
Samples processing for miRNA-seq:  
Total RNA was extracted from purified hepatocytes six days after tamoxifen 
injection with Trizol® reagent (Life Technologies). For each set of conditions, we 
analyzed four distinct hepatocyte preparations by deep sequencing on an Illumina 
platform (Fasteris, Switzerland). The reads generated by the HiSeq were analyzed 
with miRDeep2 and miRAnalyzer software (See Supporting Materials). 
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Chromatin sonication and immunoprecipitation 
The ChIP protocol was adapted from that of Nelson [25], as previously described 
[9](See Supporting Materials).  
 
Human samples 
We included 44 patients treated for liver cancer at Cochin hospital in this study 
(Table S3). All tumor samples were frozen after surgery.  
 
RNA extraction and RT-qPCR 
Total RNA was extracted from purified hepatocytes with Trizol® reagent (Life 
Technologies). Levels of miRNAwere determinedon 2 ng total mRNA, with a specific 
Taqman miRNA assay (Applied Biosystems). Levelof cyclin D1 and HNF-4α was 
determined on 100 ng total mRNA relative to 18S RNA (see Supporting Materials).  
 
Statistical analysis 
We assessed the significance of differences between two groups of samples in 
Wilcoxon tests if n<30 and Student tests if n>30. ANOVA was used to compare three 
groups of samples. P<0.05 was considered statistically significant. 
 
RESULTS 
 
MiR-34a is induced following β-catenin activation 
We searched for candidate microRNAs regulated by β-catenin in hepatocytes, by 
deep-sequencing the miRNAs expressed in the pre-tumoral Apc deletion (ApcKO) 
model, in which there is pan-lobular β-catenin overactivation, and comparing the 
results with those for wild-type (wt) hepatocytes. A statistical analysis showed that 
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123 miRNAs discriminated between ApcKO and wt hepatocytes (Tables S1 and S2), 
and that these miRNAs mostly targeted the Wnt/β-catenin pathway (Figure S1). We 
confirmed that miR-375 levels were significantly decreased by β-catenin activation 
(Table S2), as reported in HCCs with β-catenin mutation [13]. We also identified 54 
miRNAs generated from the imprinted Dlk1/Gtl2 locus as positive targets of β-catenin 
(Table S1). We discarded this locus for further studies, as this is not a relevant target 
of β-catenin in human HCCs (see the supplemental materials, Tables S1, S3 and 
Figure S2). We thus focused on miR-34a, which was induced by a factor of about 
three after β-catenin activation, with respect to wild-type hepatocytes, in the miRNA-
seq analysis (Table S1), and in qPCR (Figure 1A). This miRNA displayed the most 
significant induction following β-catenin activation after the miRNAs from the 
Dlk1/Gtl2 locus, and its overexpression in HCC with β-catenin mutation has already 
been reported [18]. We collected 24 human tumors with a mutation of CTNNB1 
leading to β-catenin activation, and 20 tumors without CTNNB1 mutation. This cohort 
covered the major etiologies observed for HCC (HBV, HCV, alcohol abuse) (Table 
S3). In our cohort of patients, miR-34a levels were higher in tumors than in normal 
tissue (by a factor of 2 in the absence of CTNNB1 mutation, and 5 in presence of 
CTNNB1 mutation, Figure 1B); this induction was significantly stronger in tumors with 
β-catenin mutations (p<0.005). The overexpression of miR-34a in tumors with 
mutations of β-catenin was correlated with a context of HCV infection or no particular 
risk factors (Figure 1C). The sample size was too small to obtain a significant 
difference in miR-34a overexpression as a function of alcohol abuse status (Figure 
1C). The overexpression of miR-34a was confirmed by in situ hybridization in another 
panel of tumors with β-catenin mutation (Figure 1D). Thus, miR-34a is overexpressed 
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in human HCCs with CTNNB1 mutations, and could constitute a major mediator of 
the oncogenic signal initiated by β-catenin activation in hepatocytes. 
 
β-catenin directly regulates miR-34a  expression 
For confirmation of miR-34a regulation by β-catenin, we transfected isolated wt 
and ApcKO hepatocytes with a siRNA against β-catenin. β-catenin silencing 
decreased miR-34a levels by about 47% for wt hepatocytes and 33% for ApcKO 
hepatocytes (Figure 2A). We thus investigated whether β-catenin could directly 
control miR-34a expression, by ChIP experiments with an antibody against TCF-4 (T-
cell factor 4), the main LEF/TCF factor associated with β-catenin in liver[9], and an 
antibody against β-catenin. We measured the binding of TCF-4 and β-catenin tosites 
upstream from miR-34a identified as a TCF-4 binding site in our ChIP-seq data[9]. β-
catenin activation led to a significant increase in the binding of TCF-4 (Figure 2B) and 
β-catenin (Figure 2C) to a site 21kb upstream from miR-34a. β-catenin binding was 
also significantly increased following Apc depletion on a more proximal TCF-4 site 
(Figure S3). Overall, our data suggest that an excess of β-catenin could significantly 
increase miR-34a transcription in hepatocytes. 
 
MiR-34a zonal redistribution after β-catenin overactivation 
We then assessed the hepatic distribution of miR-34a by in situ hybridization. 
Exceptions, such as cyclin D1 [23], are known, but the direct targets of β-catenin are 
generally expressed in pericentral (PC) hepatocytes, in which Wnt/β-catenin 
signaling is activated [7]. Counterintuitively, in normal livers, miR-34a was found to 
be preferentially expressed in hepatocytes around the portal vein and, more 
particularly, in bile duct cells (Figure 3A). For confirmation of this prevalence of miR-
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34a in the periportal (PP)subpopulation, we isolated PP hepatocytes and PC 
hepatocytes separately, by injecting digitonin into the central vein and the portal vein, 
respectively. This differential perfusion also showed that PP samples were enriched 
in miR-34a (Figure 3B). The results were non-significant, since using this technique, 
biliary cells are mainly lost during washing steps. In addition, β-catenin overactivation 
led to a loss of miR-34a zonation, and to miR-34a expression of in all hepatocytes 
(Figure 3A). In conclusion, miR-34a appears to be expressed in hepatocytes 
throughout the liver only when β-catenin is overactivated.  
We then searched the DIANA database (http://diana.imis.athena-
innovation.gr/DianaTools/index.php?r=microT_CDS/index), a database with 
experimentally validated targets for miRNAs, for potential targets of miR-34a. 
Number of potent targets have been identified (Table S4), but we focused on three 
interesting proteins: LEF-1, a transcription factor associated with β-catenin, caspase 
2, recently identified as a direct target of miR-34a in the liver [26], and HNF-4α, which 
we recently showed to be an antagonist of β-catenin in the liver[9]. These opposing 
activities result in a reciprocal physiological distribution in the liver, with miR-34a 
found in biliary cells (Figure 3A) and HNF-4α in hepatocytes, consistent with the 
hypothesis that miR-34a could repress HNF-4α expression in biliary cells [27]. 
 
MiR-34a inhibition improves HNF-4α transactivation capacity in hepatocytes 
displaying β-catenin-activation 
We confirmed by western blotting that the levels of HNF-4α, caspase 2, and LEF-1 
proteins (Figure 3C) were inversely correlated with miR-34a levels in ApcKO mice. 
Similarly, the overexpression of miR-34a in human HCCs with CTNNB1 mutations 
was also associated with weaker immunostaining for HNF-4α in these tumors (Figure 
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S4). In a previous study, we showed that β-catenin impaired the transcriptional 
activity of HNF-4α on a luciferase reporter gene under the control of an HNF-4α-
response element (FOP)[9]. Having shown that β-catenin induces miR-34a, which 
could in turn regulate HNF-4α levels, we investigated the involvement of miR-34a in 
the antagonism between HNF-4α and β-catenin in ApcKO hepatocytes. An inhibitor of 
miR-34a based on locked nucleic acid technology (LNA-34a), which consists of the 
complementary sequence for miR-34a with a methylene group in the ribose, 
significantly activated the FOP reporter (Figure 3D). A mimic of miR-34a had no 
effect, probably due to the maximal miR-34a overexpression in ApcKO hepatocytes 
(Figure 3C). In conclusion, miR-34a represses HNF-4α transcriptional activity, and 
appears to be involved in the β-catenin/HNF-4α antagonism in our model of β-catenin 
overactivation. 
 
MiR-34a is induced in tumors displayingβ-catenin activation 
We then assessed the level of miR-34a in liver tumours mutated for β-catenin in 
mice. We compared 35 tumors with seven normal tissues obtained from wt mice that 
had received tamoxifen injections. MiR-34a levels in these tumors were twice those 
in normal tissues (Figure 4A). HNF-4α mRNA levels in these tumors were also half 
those in normal tissues (Figure 4B), confirming its tumor suppressor role in the 
liver[28, 29]. Interestingly, the tumors with the highest miR-34a levels also had the 
lowest HNF-4α levels (Figures 4C and 4D). The deregulation of miR-34a in these 
tumors was independent of p53 mRNA levels (Figure S5), despite miR-34a being a 
target of p53[30]. Finally, we confirmed that overexpression of miR-34a in tumors 
with β-catenin overactivation, by in situ hybridization, was associated to a loss of 
HNF-4α (Figure 4E). 
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MiR-34ainhibitionby a locked nucleic acid  
These data highlight the unique oncogenic role of miR-34a in a context of β-
catenin overactivation. This led us to try to block miR-34a activity with a LNA, which 
has proved promising in human liver disease [31]. We assessed the efficacy of this 
approach in cultures of hepatocytes isolated from wt and ApcKO mice. No change in 
the morphology of hepatocytes transfected with LNAs was observed, on microscopy, 
72 hours after transfection (data not shown). The efficacy of LNA-34a was assessed 
by cotransfection with a luciferase reporter construct with a miR-34a binding site in its 
3’UTR. As expected, following cotransfection with LNA-34a, miR-34a activity was 
impaired, resulting in an increase in luciferase activity (about three times higher than 
that obtained after cotransfection with LNA-scramble, Figure 5A). The LNA efficacy 
was also confirmed by western blotting for HNF-4α: HNF-4α levels were higher in the 
presence of LNA-34a (Figure 5B).  
 
LNA-34a impairshepatocyte proliferationafterβ-catenin overactivation 
We then investigated the effect of LNA-34a on the proliferation of hepatocytes. We 
used the xCELLigence system, which measures cell impedance in real-time, through 
the use of gold microelectrodes placed under each well. WT hepatocytes underwent 
one round of cell division, due to the proproliferative effect of tamoxifen and 
collagenase perfusion (Figure S6A). WT hepatocytes had a lower cell proliferation 
index than ApcKO hepatocytes (Figure S6A), confirming that an absence of Apc leads 
to hepatocyte hyperproliferation[8]. Transfection with LNA-34a significantly impaired 
ApcKO hepatocyte proliferation (35% inhibition), but had no effect on wt hepatocytes 
(Figure 5C). Similar results were obtained with the Cell Titer assay, measuring the 
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reduction of tetrazolium in formazan, a process dependent on NADPH (data not 
shown). The activity of lactate deshydrogenase in cell supernatant was not altered 
following LNA-34a transfection, suggesting an absence of LNA-34a toxicity (Figure 
S6B). This suggests that LNA-34a has a specific antiproliferative effect on 
hepatocytes displaying β-catenin overactivation.In addition, the LNA-34a transfected 
three days successively increased the amount of caspase-2 propeptide, as well as 
caspase-2L, its proapototic isoform, and also decreasedthe level offull-length PARP-
1, suggesting its increased cleavage (Figure 5D). This was not observed for wt 
hepatocytes (Figure S6C). In vivo, the LNA-34a injected to mice only increased 
caspase-2L level in ApcKO mice (Figure S6D).In conclusion, LNA-34a promotes a 
pro-apoptotic signal in the ApcKO hepatocytes. 
Cyclin D1 has been identified as a target of miR-34a [32]. We therefore assessed 
cyclin D1 levels after transfection with LNA-34a. Contrary to expectations, cyclin D1 
protein and mRNA levels, at a lower extent,were decreased in the presence of LNA-
34a (Figure 5E).  However, this is consistent with the antiproliferative effects of LNA-
34a on ApcKO hepatocytes (Figure 5C). The loss of cyclin D1 may be a consequence 
of the increase in HNF-4α amount in the presence of LNA-34a (Figure 5B), as HNF-
4α has been shown to repress cyclin D1 [33] (Figure 6E). In agreement with this 
hypothesis, no change in cyclin D1 protein and mRNA levels was observed when 
ApcKO hepatocytes also lacking hnf-4α, were transfected with LNA-34a (Figure 6A). 
LNA-34a had also a weaker antiproliferative effect on these hepatocytes isolated 
from a transgenic mouse model, in which both Apc and hnf4a had been deleted by 
Cre-Lox strategy(Figure 6B). The higher proliferation rate observed for hnf4/ApcKO 
hepatocytes in the presence of LNA-34a was associated to a minor induction of 
caspase-2L level, even if caspase-2 propeptide was efficiently increased (Figure 6C); 
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PARP amount was also not altered in this case (Figure 6C). Finally, we realized ChIP 
experiments with an antibody against HNF-4α in ApcKO hepatocytes,and analyzed 
the binding of HNF-4α in the presence of LNA-34a on two binding sites identified in 
published ChIP-seq experiments done in HepG2 cells and in murine livers (Figure 
S7). We showed that the binding of HNF-4α to cyclin D1 promoter tended to 
increasefollowing exposure to LNA-34a, in particular for peak 1 (Figure 6D). This 
finding corroborates that HNF-4α mediates the decrease in cyclin D1 levels in 
response to LNA-34a. In conclusion, following its overactivation, β-catenin binds to 
the miR-34a promoter, thereby increasing its expression. MiR-34a in turn decreases 
the amount of HNF-4α, leading to increases in cyclin D1 transcription, and 
hepatocyte proliferation (Figure 6E).  
 
MiR-34a inhibition reduces tumor progression in ApcKO mice 
We thus developed a tumor suppressive strategy based on miR-34a inhibition, 
which could constitute the first targeted therapy for liver tumors displaying β-catenin 
activation. We assessed the impact of LNA-34a on liver tumor progression in an 
ApcKO context. Once the tumors became detectable on ultrasound scans, we injected 
LNA-34a (10 mg/kg) once weekly, and followed tumor development twice monthly, by 
2D-ultrasound (Figure S8). We found that LNA-34a slowed the progression of tumors 
displaying β-catenin activation, to rates about half those for untreated tumors (Figure 
7A and S8). This treatment also inhibited the development of new tumors, with only 
one new tumor on average occurring on LNA-34a treatment, versus four on LNA-
scramble treatment (Figure 7B). As expected, HNF-4α levels increased and cyclin D1 
levels decreased in tumors treated with LNA-34a (Figure S9A). Even if cyclin D1 
level was impaired, Ki-67 labeling was similar in tumors treated with LNA-34a, and in 
 16 
those treated with the scramble LNA (Figure S9B). Similar results were obtained with 
western-blots for phospho-Histone H3 and cyclin A labeling (data not 
shown).However, LNA-34a promoted caspase 2 and 3 activation in tumors, in both 
western-blot and immunohistochemistry experiments, confirming its pro-apoptotic 
effect (Figures 7C and 7E), with minor effects on non-tumoral liver (Figure 7D).Thus, 
treatment based on the use of LNA-34a could reduce tumor development through an 
increase in HNF-4α levels, leading to a loss of cyclin D1, and through a pro-apoptotic 
program associated with the induction of caspase 2 and caspase 3 cleavage. 
 
DISCUSSION 
 
The microRNA miR-34a has been widely described as a tumor suppressor. 
Indeed, its expression is frequently impairedin various cancers following an 
hypermethylation of its promoter[20], including breast and prostate cancers[34, 35]. A 
preclinical trial is currently underway with a mimic of miR-34a encapsulated into 
liposomes in various murine models of solid tumors (miRNATherapeutics, 
http://www.mirnarx.com/pipeline/mirna-MRX34.html). However, the role of miR-34a in 
liver tumorigenesis remains unclear. One study suggested that miR-34a level 
decrease in HCC [22], andis associated to migration and invasion [21], but another 
two studies reported the induction of miR-34a in HCC samples [17, 18], in HCV+ 
sera[36], and in HCC cells in response to alcohol [26]. Our findings suggest that miR-
34a is an oncogenic mediator in tumors displaying β-catenin activation, both in mice 
and humans, confirming the data reported by Pineau et al. [18]. Our results could 
reconcile the data of Lou and Li, which suggested that miR-34a was lost in two thirds 
of the HCCs studied [21, 22]. These samples corresponded mostly to HBV+ tumors, a 
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subgroup with a lower frequency of CTNNB1 mutations [10]. The other third of 
patients in their cohort, with HCV infection, displayed an increase in miR-34a 
expression, and this group is likely to be enriched in CTNNB1 mutations, according 
to transcriptomic classifications[4, 5]. In our cohort, tumors without β-catenin 
mutations displayed heterogeneity in terms of miR-34a amount. A greater 
understanding of this variability would be very useful, 
In our study, we used a LNA approach to block cell cycle progression (Figure 5C), 
to decrease cyclin D1 protein levels (Figure 5E), and to induce caspase-2 activation 
(Figure 5D), in isolated ApcKOhepatocytes. The decrease in cyclin D1 protein levels 
was actually due to HNF-4α, because the invalidation of hnf4a in the ApcKO model 
resulted in an absence of change in cyclin D1 levels (Figure 6A), and a smaller 
decrease in cell proliferation (Figure 6B), in the presence of LNA-34a. In addition, 
LNA-34a increases HNF-4α protein level (Figure 5B), but also its transcriptional 
activity on a luciferase construct under the control of a HNF-4 responsive element 
(Figure 3D), and on cyclin D1 promoter (Figure 6D).Thus, HNF-4α, a tumor 
suppressor in the liver [28], appears to be a key mediator of the effects of miR-34a in 
the ApcKO model (Figure 6E). More importantly, miR-34a emerges as a crucial 
component of the oncogenic signal induced by β-catenin in hepatocytes.  
In normal livers, miR-34a was particularly expressed in bile duct cells (Figure 3A 
and 3B). This specific pattern of expression may hinder the accumulation of HNF-4α 
protein in the biliary cells, which is required for bile cell lineage 
patterning[27],probably independently of β-catenin, which is not activated in normal 
bile duct cells[37]. Thepattern of miR-34a expression is not consistent with the usual 
model, in which β-catenin targets are located near the central vein. Cyclin D1 is one 
exception to this model;its pattern of expression is not restricted to the PC zone [23]. 
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Interestingly, the region bound to TCF-4/β-catenin located in miR-34a promoter 
contains no classical Wnt-responsive element, suggesting that the control on miR-
34a is complex (Figure 2B). This complexityis lost when β-catenin is overactivated, 
as in HCCs.  
The key finding of this study was the decrease in liver tumor growth afforded by 
the delivery of LNA-34a (Figures 7A and S8). Only a few studies to date have 
demonstrated the potency of miRNA-based approaches to cancer treatment. 
However, the great advantage of this approach for HCC is that these molecules are 
preferentially delivered to the liver [38]. The first authorization for clinical trials with 
miRNA-based therapies, concernsthe LNA against miR-122 (miravirsen) for 
HCVtreatment[31]. The use of these modulators poses a number of challenges, 
particularly for their specificity. Our therapeutic approach, involving the inhibition of 
miR-34a, displays no toxicity (Figure S6B), and has the great advantage of restoring 
the tumor suppressor HNF-4α, targeting cyclin D1 and the metabolic pathways 
regulated by HNF-4α (Figure S9). In addition, this approach may also alter the anti-
inflammatory loop orchestrated by HNF-4α, controlling interleukin-6 production by 
hepatocytes [39, 40]. More importantly, the LNA-34a promotes a pro-apoptotic signal 
orchestrated by caspase 2 and 3 (Figure 7C-E). In conclusion, our data reveal that 
miR-34a inhibition mainly induces a pro-apototic program centered onto caspase-2, 
and could affect cell proliferation through cyclin D1 inhibition. However, the fact that 
Ki-67 and cyclin A labeling were not affected by LNA-34a treatment, suggeststhat 
miR-34a effects on cell proliferation are more complex.  
In conclusion, despite the current preclinical trials being run by miRNAtherapeutic, 
our findings suggest that the precise differential diagnosis of HCC, including an 
assessment of the mutational status of β-catenin, for which miR-34a inhibitors would 
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be more appropriate than miR-34a mimics, is vital. Using this approach, we hope to 
affect not only the tumor itself, but also its environment, through the first effective 
targeted therapy for one third of HCCs worldwide. 
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FIGURE LEGENDS 
Figure 1: miR-34a is induced following β-catenin activation in mouse 
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hepatocytes and in HCC samples from patients.  
A: miR-34a induction in ApcKO hepatocytes isolated at day 6 after tamoxifen injection 
in miRNA-seq was confirmed in 15 samples by RT-qPCR relative to snoRNA135.B-
D: miR-34a levels, relative to RNU24 and RNU49 levels, in 24samples of HCC with 
β-catenin mutation (mut-β-cat) and 20 samples of non-mutated (non-mut-β-cat) HCC, 
as compared with normal tissues. HCV: hepatitis C virus; HBV: hepatitis B virus; OH: 
alcohol exposure; others: no specific etiology, ns: non-significant. C: Detection of 
miR-34a in HCC samples with β-catenin mutation byin situ hybridization.  
 
Figure 2: miR-34a is induced following β-catenin activation, through the direct 
binding of β-catenin. 
A: wt (CTRL) and ApcKO hepatocytes were transfected 3 days after tamoxifen 
injection with 100 nM of a siRNA against β-catenin for 24 h. Results are shown as the 
mean RQ (relative quantity) values for miR-34a for five independent experiments ± 
SEM, as compared with scramble siRNA. B-C: TCF-4 (B) and β-catenin (C) binding 
to a site 21 kb upstream from the miR-34a promoter in wt (CTRL) and 
ApcKOhepatocytes at day 6 after tamoxifen injection, as compared with the isotype 
control (IgG). Results are expressed as the binding value ± SEM normalized with 
respect to three control sites in the myc and Alb genes. The means of at least three 
independent experiments are shown.  
 
Figure 3A-B: miR-34a induction following β-catenin activation is associated 
with lower HNF-4α level and activity. A: miR-34a localization by in situ 
hybridization with LNA-34a in comparison with a scramble LNA. PP: periportal zone; 
PC: pericentral zone. B: miR-34a level assessed by RT-qPCR on wt (CTRL) 
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hepatocytes isolated by digitonin/collagenase perfusion, and expressed as 
previously. ns: non-significant.# represents the number of samples tested.C: HNF4α 
protein expression in comparison with miR-34a levels in ApcKO hepatocytes, by 
comparison to wt hepatocytes (CTRL). # represents the sample number. D: ApcKO 
hepatocytes transfected with the FOP construct (HNF-4α response element), with 
LNA-scramble or LNA-34a or a mimic of miR-34a. Results are expressed as the 
mean luciferase induction of three independent experiments carried out in duplicate. 
 
Figure 4: miR-34a is induced in tumors from ApcKO mice. 
A: miR-34a levels in 42 tumors with β-catenin mutations are compared with those for 
normal tissues, and are expressed as previously described. B-D: HNF-4α levels, 
relative to 18S, are determined by qPCR, and represented as previously, as 
compared with non-tumor tissues. D: Correlation between miR-34a and HNF-4α RNA 
levels. E: Correlation between miR-34a byin situ hybridization and HNF-4α by 
immunohistochemistry in ApcKO tumors.NT: non-tumoral tissue, Tum: tumor. 
 
Figure 5: LNA-34a inhibits ApcKO hepatocyte proliferation, decreases cyclin D1 
levels, and promotes apoptosis. A: Isolated ApcKO hepatocytes were transfected 
with a luciferase construct with a miR-34a binding site in 3’UTR, and with LNA-
scramble or LNA-34a. Results are expressed as the mean luciferase activity in three 
experiments performed in duplicate. B: Confirmation of LNA efficacy on HNF-4α 
protein levels. Isolated ApcKO hepatocytes were transfected with LNA-scramble or 
LNA-34a for 48 h. C: Cell proliferation was assessed, for 48 h on wt or ApcKO cells, 
transfected with LNA-scramble or LNA-34a. Results are expressed as the mean % 
proliferation normalized against cells treated with LNA-scramble at time t in three 
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independent experiments carried out in quadriplicate ± SEM. Caspase 2 and PARP 
protein level (D), andCyclin D1 protein and mRNA levels (E) in isolated ApcKO 
hepatocytes transfected with LNA-scramble or LNA-34a for 48 h. 
 
Figure 6: LNA-34a impact depends on HNF4α expression 
A: Cyclin D1 mRNA and protein level in isolated hnf-4αKO/ApcKO hepatocytes 
transfected with LNA-scramble or LNA-34a for 48 h. B: Cell proliferation of ApcKO or 
Apc/hnf-4αKO cells, transfected with LNA-scramble or LNA-34a for 48 h. Results are 
expressed as in figure 5. C: Caspase 2 and PARP protein level protein levels in 
isolated hnf4/ApcKO hepatocytes transfected with LNA-scramble or LNA-34a for 48 h 
D:HNF4α binding to the cyclin D1 promoter in ApcKOhepatocytes, as compared with 
the isotype control. Results are expressed as in figure 1. They represent the means 
of at least three independent experiments. E: The cascade orchestrated by miR-34a. 
 
Figure 7: LNA-34a slows the development of tumors from APCKO mice, by 
activating caspases 2 and 3. A: Tumor development was followed by 2D 
ultrasound. The results are expressed as the fold-change in volume over 15 days ± 
SEM normalized with respect to t0, for mice with and without LNA-34a treatment (10 
mg/kg). B: Numbers of new tumors detected during the treatment of mice with LNA-
scramble or LNA-34a. C-E: caspase 2 and 3 expression. Immunohistochemistry 
experiments have been performed on parallel sections. 
 
 
